Home / Transcripts / Definium Therapeutics, Inc. (DFTX) · November 9, 2026

Definium Therapeutics, Inc. (DFTX) Earnings Call Transcript

November 9, 2026

NASDAQ US Health Care Pharmaceuticals earnings 47 min

Earnings Call Speaker Segments

Gita Jain executive
#1

Good afternoon, everyone. My name is Gita Jain, and I serve as Head of Investor Relations. Thank you all for being with us on this call covering Definium Therapeutics' third quarter 2026 financial results along with recent business highlights. For this session, all participants are in listen-only mode. A live webcast is available in the Investor section of Definium' website, and a replay will be made available once the webcast concludes. Today's call will be led by Rob Barrow, our Chief Executive Officer, and joining him are Dr. Dan Karlin, our Chief Medical Officer, Brandi Roberts, our Chief Financial Officer, and Matt Wiley, our Chief Commercial Officer. During this call, we'll be sharing forward-looking statements. Those cover possible safety and efficacy of our product candidates, their clinical and regulatory advancement, when we might file with regulators and how broad those filings could be, our commercial readiness efforts, how long our cash will last, and what we expect, plan, and foresee ahead. Such statements carry risks and uncertainties, among them the ones laid out in our filings with the SEC and with Canadian securities regulators that apply, such as the Form 10-K annual report and the Form 10-Q we filed today. Management's assumptions, opinions, and estimates as of today, November 9th, 2026, form the basis for these forward-looking statements. We caution you against relying too heavily on them. Except where the law requires it, Definium undertakes no duty to update them. Having said that, I'll now hand things over to Rob. Rob?

Rob Barrow executive
#2

Thanks, Gita, and thanks to all of you for being with us today. For Definium, the third quarter represented a significant turning point. With positive phase III results across three studies and two large psychiatric indications, we've gone past showing the promise of DT120 ODT to building a compelling body of evidence supporting its potential to fundamentally change the way anxiety and depression are treated; in our view, these results put DT120 in position to become an important new treatment option for millions of people who still face significant unmet needs, and they reinforce our conviction that we have an opportunity to help shape the future of psychiatric care. Equally important, we're making meaningful progress toward realizing that opportunity. DT120 has now received two FDA breakthrough therapy designations, which reflects the potential of this program to address serious conditions with substantial unmet need. Our engagement with FDA remains constructive, and we're advancing with urgency toward our planned NDA filing in the first half of 2027. Our focus isn't simply on reaching the next regulatory milestone; it's on doing the work necessary to be ready to deliver DT120 to patients and healthcare providers if approved. That preparation extends across the organization. We're building the commercial capabilities, deepening our engagement with the medical community, and developing the scientific and educational foundation that will be important to introducing a fundamentally different treatment approach. We recognize that realizing the full potential of DT120 will take more than strong clinical data; it will take a thoughtful approach to regulatory execution, access, provider education, and ultimately, the patient experience. Those priorities are shaping how we're building Definium for its next chapter. At the same time, we're continuing to advance the pipeline with potential beyond DT120. Today, we shared initial results from our DT402 study in adults with autism spectrum disorder, which showed encouraging signals across measures of socialization, communication, and functional outcomes. These findings support our continued investment in DT402 and underscore our ambition to build this company with multiple products that have the potential to make a meaningful difference across therapeutic areas. We enter the next phase of our journey with strong clinical validation, growing regulatory momentum, and an organization increasingly positioned to translate innovation into impact. There's still important work ahead, and we believe Definium is well-positioned to pursue the opportunity in front of us and ultimately bring new treatment options to the people who need them. With that, I'll turn the call over to Dan to provide more details on our clinical progress.

Dan Karlin executive
#3

Thanks, Rob. We're happy with the consistent DT120 clinical profile shown across Emerge, Voyage, and Panorama. A single 100 µg dose generated fast, lasting improvements in the disorders in every study. Voyage enrolled 214 participants with moderate to severe GAD and hit its primary endpoint plus all key secondary efficacy endpoints. At week 12, DT120 demonstrated a 5.4-point placebo-adjusted improvement on the Hamilton Anxiety Rating Scale, or HAM-A, with a P-value of less than 0.0001 and a Cohen's d effect size of 0.81. Improvement appeared as early as day one at the first HAM-A assessment at week one and persisted through week 12. Panorama showed similar results in 245 participants. At the 100 µg dose, we saw a 5.1-point improvement versus placebo on the HAM-A at week 12, with a P-value below 0.0001 and a Cohen's d of 0.64. That trial hit its primary endpoint along with all key secondary efficacy endpoints. The 50 µg functional control provided additional support for how interpretable the efficacy is and reinforced why we selected the 100 µg dose. Our positive Emerge results, which we announced in June, strongly support the DT120 program in MDD. Emerge met its primary endpoint and every key secondary endpoint, demonstrating a rapid, clinically meaningful, and durable treatment effect following a single dose, with efficacy apparent as early as day one and maintained through week 12. Given those findings, the FDA awarded breakthrough therapy designation to DT120 ODT for MDD, which adds to the breakthrough therapy designation it had already received for GAD. In the double-blind portions that were completed across all three trials, DT120 was generally well tolerated; there were no serious adverse events linked to the drug and no signal of suicidality. The majority of treatment-emergent adverse events appeared and cleared while the dosing session was being observed. The way treatment sessions unfolded was predictable and manageable. On average, participants finished the standardized end-of-session checklist in roughly six hours, and this held consistently across the studies. Enrollment is progressing nicely for Ascend, our fourth phase III trial and the second one in MDD, and we anticipate top-line results in 2027. Also in 2027, we expect to kick off Haven, a phase III PTSD study — that's post-traumatic stress disorder. There's still a major unmet need in PTSD, and given the clinical profile seen in GAD and MDD, we see a strong rationale for testing DT120 in this indication. The plan is to enroll roughly 200 participants, with the primary endpoint being change at week eight on the Clinician-Administered PTSD Scale for DSM-5, or CAPS-5. With the DT120 clinical program moving forward, our medical affairs group—already sizeable—is being expanded further. That includes our field-based medical science liaisons, whose job is to interact with healthcare professionals in order to understand and provide education about the disease burden, the evolving treatment environment, and the expanding evidence base behind DT120. As we get ready for regulatory submission, their efforts complement our clinical work and in the end help make certain that the medical community clearly grasps the data and the possible part DT120 could play in treating anxiety and depression. Now shifting to DT402 for ASD. Our phase II-A trial used an open-label, single-dose design, and we aimed to characterize DT402's pharmacodynamic and clinical effects while also exploring changes in social behavior and experience measures, communication, and other functional outcomes. Once five participants were enrolled, we were able to detect enough of a signal to stop the study. During treatment, multiple measures showed improvement, including reduced rigidity and fixation, increased engagement in social settings, greater empathy and closeness to others, and decreased anxiety and irritability. DT402 was well tolerated; euphoria, fatigue, and enhanced relaxation were the most frequent adverse events. This was a small, early-stage study, and the findings should be considered within that context. All the same, seeing steady gains on a range of measures is heartening and justifies further work. A trial is slated to begin in 2027 examining how safe multi-day dosing regimens are and what clinical activity they show. ASD is likewise a field with major unmet need, especially for treatments capable of targeting the central difficulties of social perception and communication. Through DT402 we have a continuing chance to build out our pipeline while staying tightly connected to our scientific know-how and mission. All told, the scope and reliability of the DT120 results, alongside encouraging early DT402 findings, leave Definium holding a possible near-term commercial product as well as a strong second asset. At this point I'll hand things over to Matt. Matt?

Matt Wiley executive
#4

Thanks, Dan. The DT120 data's robustness and consistency let us plan for launch with growing clarity and ongoing urgency. We keep building out the commercial infrastructure and capabilities required to support DT120 should it be approved. Our emphasis is on turning that strong clinical profile into a launch model that serves patients, providers, and payers. We've moved forward on our market access strategy, distribution planning, patient services, commercial operations, and field deployment plans, and we're continuing to build the infrastructure needed to support the supervised treatment model. Provider and site readiness matter greatly to a successful launch. We're working with the established and expanding ecosystem of interventional psychiatry providers to evaluate capacity, workflow, and infrastructure needs and to spot chances for extra support well before launch. Those insights directly shape how we design our field organization, develop patient services, and equip providers to deliver DT120. Patients sit at the center of our commercial planning; we recently broadened our outreach by hiring a head of patient advocacy, who will help push forward our important work with patients and advocacy organizations and bring their perspectives into our approach; this will complement our ongoing marketing and patient services efforts, helping us sharpen our grasp of the patient journey, pinpoint barriers to care, and build education and support resources that can help patients access treatment. Our aim isn't merely to make DT120 available; it's to establish the conditions for rapid, responsible adoption and a strong patient and provider experience; we're planning our first Commercial Day in the first half of 2027. There, we'll share a more detailed view of the market opportunity for DT120, our go-to-market approach, and our launch preparations. The key takeaway is that we're moving past commercial planning and putting our strategy, infrastructure, and capabilities in place for a potential launch. I'll now hand the call to Brandi for our financial results.

Brandi Roberts executive
#5

Thanks, Matt. As of September 30th, 2026, our cash equivalents and investments stood at roughly $1.05 billion, versus $411.6 million on December 31st, 2025. Given our present operating plan and the milestones we anticipate, we believe these resources will carry planned operations into 2030. R&D expenses came in at $46.1 million for Q3 2026, up from $31 million during the same quarter in 2025. That rise mostly reflected greater personnel-related costs tied to growing our R&D organization, along with more spending on the DT120 development program. G&A expenses totaled $26.1 million for the third quarter of 2026, compared with $14.7 million in the same period of 2025. The growth mainly reflected investments in corporate and government affairs, commercial preparedness, and personnel as we built out organizational capabilities, plus higher legal and patent costs. On the whole, operating expenses for the quarter matched what we had expected. As we anticipated, spending eased somewhat relative to the second quarter as we worked through a number of key clinical readouts while continuing to put money into the capabilities and infrastructure required to get ready for possible commercialization. Net loss for Q3 2026 was $51 million, versus a net loss of $67.3 million in the same period of 2025. That smaller net loss was chiefly due to a gain from the change in fair value of our 2022 financing warrants and greater interest income, partly offset by higher operating expenses. Not many companies at our stage enjoy the financial strength we hold today. It lets us invest decisively behind DT120 and the opportunity we see in front of us without compromising either the scale or the quality of our launch preparation. We plan to make use of that advantage. With potential indications in GAD and MDD — two of psychiatry's largest areas — and no new treatment approved for GAD in 20 years, we think the opportunity for DT120 is substantial. That is why investing appropriately right now matters so much. We believe the right investments today can deliver significant returns over the long term, and we stay sharply focused on maximizing DT120's potential and creating value for patients, providers, and shareholders; with that, I'll hand the call back to Rob.

Rob Barrow executive
#6

Thank you, Brandi. What we reported today is the product of many years of rigorous science and disciplined execution. For DT120 in GAD and MDD, we now have three positive phase III trials, along with breakthrough therapy designations in both of those indications, and our NDA filing remains on schedule for the first half of 2027. Our confidence is high in both the clinical evidence and the commercial strategy for DT120 ODT, and we stay focused on our vision of enabling exceptional outcomes and care for the millions of patients who live with GAD, MDD, PTSD, and other mental health disorders. As we close out 2026, we do so with exceptional momentum and more than $1 billion available to invest in delivering on that vision. I want to thank the patients, investigators, employees, and partners whose commitment has made this progress possible, and I look forward to sharing further updates as we move through 2027 and beyond. With that, we are happy to take your questions.

Tessa Romero analyst
#7

Hello, Rob and the team. Many thanks for fielding our questions tonight. We have just the one. Could you share whether the pre-NDA meeting for DT120 ODT has already occurred, and if it hasn't, when it is expected to? Also, what is your plan for communicating what comes out of that meeting, and would that happen only after you receive the meeting minutes? Thank you.

Rob Barrow executive
#8

Thanks a lot for that question, Tess. Our engagement with FDA has us genuinely enthusiastic, and so does all the dialogue that continues. As you know, we've been talking with the agency on a very regular basis for the past several years, and certainly across the past several months, given that we now have phase III data. As you pointed out, it's generally once the meeting minutes are in hand that we're able to disclose specifics from meetings. We don't want to get ahead of ourselves on anything, but that constructive, ongoing dialogue keeps us very enthusiastic about the path ahead, and we're proceeding rapidly here to get ready for an NDA filing in the first half of next year.

Analyst analyst
#9

Hi everyone, this is John, covering for Andrew. I really appreciate all the updates. Since COMP360 is anticipated to gain approval and reach the market during the first half of 2027, could you perhaps outline a few of the areas you'll be watching especially closely around launch — it might help shape how we think about our own DT120 launch, which I suppose could come roughly a year from now potentially. Are there particular things you hope to learn that are specific to COMP360 and maybe even distinct from SPRAVATO? Thank you.

Rob Barrow executive
#10

Yes. Many thanks for that question, John. At a broad level, we are naturally witnessing momentum across the whole field, and we recognize that having several possible chances for drugs to reach the market gives providers, in our view, the capacity to engage and put themselves in a position to expand the footprint where this product might potentially be delivered. So clearly, there are so many patients in such great need, and we feel quite confident about the profile of DT120. We will be tracking everything closely and obviously have our own thoughts, plans, and strategy regarding how to bring this out in the most impactful way. Absolutely, we’ll be monitoring the situation closely and working to put ourselves in the best position to launch as effectively and as broadly as possible, assuming the drug receives approval.

Tazeen Ahmad analyst
#11

Hello, and thanks for taking my question. Just one quick thing. So, if the Ascend study reads out while your initial NDA is under review, do you think you'd be able to — if there's any question about whether a second study is needed for MDD — do you think you could amend the original filing, or would you, if the FDA prefers to keep them separate, just keep them separate without trying to start any additional discussions, assuming Ascend comes back positive when it reads out? Thanks.

Rob Barrow executive
#12

Understood. Thanks so much for the question; on filing strategy, once we're in a position to share more specifics, we're certainly looking forward to doing so. Sponsors filing have a lot of avenues potentially available to them. As we think about both of these very important, very large indications, our focus is on driving the most efficient path to market and having the highest quality evidence we're able to put behind it; so we're really encouraged by the momentum with the Ascend study; it's only picked up since we had MDD data from Emerge earlier in the year; regarding the sequencing and the ability and the data that would be submitted at various points in a review cycle, I think we'll hold back on any specifics there until we're able to talk holistically about the overall filing strategy; but needless to say, we're really excited about the path forward and the ability to have an efficient process for both these indications.

Analyst analyst
#13

Hello. Matthew here, filling in for Paul. We really appreciate you taking our question, and congratulations on all the progress. From our side, with the recent Usona filing for depression, does that change your commercialization or pricing strategy at all as you think about the MDD market? Thank you very much.

Rob Barrow executive
#14

Yes. Thanks a lot for the question. At the core, no. I'm glad to have Matt Wiley elaborate more, but of course, all of us feel very close to this, and we feel very confident about how our product is positioned and its ability to meaningfully differentiate from the psilocybin products and to be in a great position. But Matt, I don't know whether you'd like to add any specifics there.

Matt Wiley executive
#15

I'd simply return to things I've said before regarding the pricing corridor—payers have told us they view that corridor as sitting somewhere in the range of $30,000 to $75,000, which is what they pay today for SPRAVATO. There's differentiated value here, as Rob mentioned. In future payer discussions, we'll be able to narrow that corridor down, but we feel fairly good about the feedback received up to now.

Analyst analyst
#16

Thanks.

Marc Goodman analyst
#17

Dan, when it comes to a PTSD study in this kind of asset, what makes it hard to run and to succeed, compared with what we're all a bit more familiar with in MDD and GAD? Thanks. If there are any.

Rob Barrow executive
#18

Yeah. Dan, would you like to go ahead and handle that one?

Dan Karlin executive
#19

Absolutely, and thanks for asking, Marc. PTSD is something we’re genuinely enthusiastic about, and although every indication brings its own distinct hurdles around patient access and similar matters, our fundamental view is that this won’t prove any harder than what we’ve already accomplished; we have great confidence in the asset, great confidence in the clinical development team that has brought us this far, and in our clinical operations people too. We’re eager to begin and to generate evidence in this novel and truly important population.

Analyst analyst
#20

Sorry, are you able to hear me?

Analyst analyst
#21

Oh, great; Yashalyn here on behalf of Gavin; we were just curious regarding DT402, might you be able to elaborate on the reason enrollment was halted following five patients and what you observed that sort of gave you confidence to proceed into the multiple dose study? And was that decision made based on pre-specified stopping rules or sort of a review of the emerging data? Thank you.

Rob Barrow executive
#22

Thanks very much. I'll hand it over to Dan to expand initially. Happy to add anything, Dan.

Dan Karlin executive
#23

Absolutely. So regarding DT402 and the study we recently completed, the objective right from the start was to identify what we'd describe as early efficacy signals. It was a single-dose, open-label study examining drug response parameters across that one dosing day. And what we had determined initially was that if a strong and consistent signal emerged, we would halt enrollment once we felt nothing further could be gained from continuing. At the stage we reached, the signal was sufficiently consistent, pointed in the right direction, carried genuinely solid magnitude, and there was no justification for continuing to enroll participants. And we feel a great deal of confidence going forward from this point.

David Amsellem analyst
#24

Hello, thank you. I have a further question regarding DT402, and I understand that we're still at an early stage of the development program, but might you be able to discuss validated scales for measuring the things you're targeting, for instance social engagement, and what you intend to use as outcome measures in the multi-dose trial; and then in addition, what did you see early on from the small number of patients during the monitoring period, and how long do you anticipate those patients will need monitoring compared with what has been incorporated and what you're seeing for DT120? Thank you.

Dan Karlin executive
#25

Yes, that is an excellent question, and it contains a few unresolved issues within it. The legacy Vineland measure applied in autism spectrum disorder does contain a distinct subscale for social communication. Making use of pre-existing validated instruments will certainly remain a component of our strategy, yet we are equally enthusiastic about demonstrating the kind of everyday improvement we anticipate from the molecule, drawing on observations to date; accordingly, our approach will combine well-established scales that have at least some track record of being presented to regulators, albeit clearly in a setting where no therapies have won approval for the core symptoms of ASD. We see room to operate in that area, and since we care deeply about measurement and about the most effective approaches to answering the questions we want to pose about the drug, we'll work collaboratively with every stakeholder across the autism and regulatory communities to make certain no chance to capture possible improvement goes unused.

Analyst analyst
#26

Hello, everyone. This is Navin, covering for Brian. I'd like to return to something and pose a follow-up question about a few of the latest developments at Usona. With the possible NDA submission they have in progress, and since they possess a commissioner's priority review voucher, we'll likely hear something about that within roughly the next two months. Because that timing lands so near your own pre-NDA meeting, and also because of how you're considering positioning MDD, might there be a chance to pause and observe how Usona's submission plays out, so you could see whether filing on the basis of one large phase III pivotal trial would also be possible for you? I'm simply wondering what your broader thinking is on this.

Rob Barrow executive
#27

Yeah. Appreciate that, Navin. Honestly, I'd say our attention has stayed on carrying out our program and following what we see as the proper route for this drug and these indications. Naturally, we keep an eye on developments in other programs, along with the regulatory landscape and everything around it. Our program and package were designed to give the strongest evidence base we can while still preserving speed and efficiency in bringing a product to a market with a very urgent need. So when we consider both GAD and MDD—the drug's profile, the path ahead, and the timing of data and submissions—we can share a bit more detail on those fronts once we reach that stage. We'll keep watching and see how things develop, but the course really won't change. We think the course we're on is the correct one, our strategy is sound, and we'll continue carrying it out just as we have from the very start of this initiative.

François Brisebois analyst
#28

All right, thank you for that question. I was just curious whether you might, taking Marc's earlier PTSD question a bit further, help us grasp a little more about the CAPS-5 and why week eight happens to be the right week for testing drugs in this area.

Rob Barrow executive
#29

Yeah, thanks Frank. I'll hand it over to Dan to address that too.

Dan Karlin executive
#30

So the CAPS is a measure of PTSD that clinicians assess and regulators accept, and essentially everyone in the field has used it; it's built on the most recent DSM-5 definition of PTSD. Week eight also carries genuine regulatory precedent, which is the reason we've settled on week eight. We will still keep our complete 12-week double-blind period, exactly as in our other studies, so double-blind data will extend out to week 12. Given our capacity to move- every scale we've employed as a primary to move from MADRS and the HAM-A, we stay extremely confident that any scale which is a dependable clinician-assessed measure of the disease state where we're likely to show efficacy won't pose a problem for us; so, a great deal of confidence as we head into this PTSD study.

François Brisebois analyst
#31

Thanks.

Matt Hershenhorn analyst
#32

Oh, hi, everyone. Congratulations on a fantastic year, and I appreciate you fielding our question; so, with phase III Haven for PTSD about to get underway, as you see it, could you discuss whatever recent remarks and perspective the VA has offered regarding the unmet need among veterans and expanding access to psychedelics, and in particular how DT120 might serve these patients? Also, do you anticipate veterans will make up a meaningful share of the Haven study? Any color would be appreciated. Many thanks.

Rob Barrow executive
#33

Yeah. Thanks a lot, Matt. One thing I believe is really important here is remembering that although PTSD is definitely a prominent diagnosis that gets a great deal of focus, plenty of veterans also struggle with anxiety and depression; so we already concentrate heavily on that population and on widening access and being able to get this to as many patients as might potentially benefit from it. When we think about PTSD specifically, and when we think about — perhaps even more importantly — potentially getting DT120 out into the world, we are deeply engaged with the VA, with numerous stakeholders, and connected to that care setting too, and we will stay that way. We intend to be at the leading edge of each of these opportunities within each of these communities. And part of the opportunity also lies in broadening the indications so that, should we succeed across all three programs, we could eventually have anxiety, depression, and PTSD all on the label; that gives us what we believe is a suitably broad entry point for trying to help as many patients as possible. Dan, I don't know whether you'd like to add anything about some of the early work with the VA.

Dan Karlin executive
#34

Yes, and as Rob mentioned, the connection we've built with the VA as a site across MDD and GAD matters a great deal to us, and naturally in PTSD too, since that's a patient population present at the VA as well. So we fully expect to collaborate with VA sites on the study, and naturally to include non-VA sites too. We want to be sure we're reflecting a truly generalizable and broad PTSD population, given that PTSD can present somewhat differently depending on where the trauma originated. So yes, at the VA, and yes, beyond the VA as well, and that's a relationship we'll keep nurturing as we go forward.

Matt Hershenhorn analyst
#35

Understood. That clears things up completely. Extremely useful. Many thanks.

Sumant Kulkarni analyst
#36

Good afternoon. Appreciate you taking our question. If DT120 gets approved for both MDD and GAD, what does your most recent market research indicate about which indication could see a faster ramp, and what particular reasons might explain any differences in uptake?

Rob Barrow executive
#37

Yeah. Thanks very much, Sumant. On a first pass — and of course I can ask Matt to add detail — I'd say that at a fundamental level, given how much these populations overlap, there are definitely distinct dynamics at work. Generalized anxiety disorder is a space where no new product has arrived in nearly 20 years, correct? The chance to genuinely offer something entirely new as a treatment option, and certainly in terms of how unique what we're doing is, is truly exciting there. Obviously, part of that also shows up in certain patterns of emphasis on diagnosing MDD across the last several years. Each has its own features that can influence that uptake curve. We're very enthusiastic about both independently, and particularly in combination. The prospect of potentially having something that could address both anxiety and depression is genuinely encouraging and genuinely exciting for us. Matt, feel free to expand on any of that.

Matt Wiley executive
#38

I'd like to add just one more thing. In earlier market research we conducted with both GAD and MDD patients — and we actually presented this at the Investor Day earlier this year — what we found is that patients who have failed multiple therapeutics, no matter the indication, are more likely to want to try DT120. Specifically, among patients who had failed five or more medications, 65% said they would be interested in trying DT120. So, going back to Rob's point, we really don't observe any differentiation by indication. What we do see is that patients in need are very likely to bring this up with their physician.

Pete Stavropoulos analyst
#39

Hello, Rob and everyone. Nice work on the quarter. About the study design for PTSD, especially patient selection—PTSD varies when it comes to trauma exposure, how long it's lasted, and psychiatric comorbidities. Do you think certain patient features might make people more likely to respond strongly to DT120, and how could those shape the enrollment criteria? Would you concentrate on this as a monotherapy, or will you proceed with patients who are on standard of care?

Rob Barrow executive
#40

Yes, thank you very much, Pete. I'll hand that question to Dan too.

Dan Karlin executive
#41

Thanks for asking that. One thing that stands out about DT120 specifically is that, as we have now demonstrated in GAD and MDD, we appear able to show efficacy across a variety of heterogeneous populations. So compared with an agent that has, let's say, a considerably narrower mechanism, we can be somewhat more agnostic regarding the finer-grained details of how the patient presents. And naturally, we will exclude comorbidities, just as we did in earlier trials, for individuals with histories of mania or psychosis. Beyond that, however, once we move into the moderate to severe PTSD category, we are going to include a fairly broad slice of that population. So the usual drug development constraints around medical comorbidities and psychiatric comorbidities apply, and we fully expect to conduct these trials as monotherapy, as we have in other indications; but that is more about interpretability and cleanliness of the data than about the ultimate intention for how the drug will be used. The most successful psychiatric drugs get established as monotherapies. In the end they become used as part of polypharmacy, sometimes to a fault. We intend to keep demonstrating our primary evidence as monotherapy while showing that the drug can be used safely as a component of a multi-drug strategy.

Pete Stavropoulos analyst
#42

Great. I appreciate you getting back to me on that.

Chris Chen analyst
#43

Hello, all. Thanks for fielding my question, and congratulations on a strong quarter. I just wanted to bring us back to DT120. Since you've now had additional time to examine the data from the three trials, could you offer any updates regarding how patient profile might be affecting response and remission rates? Can you identify any key drivers that might be distinguishing responders from non-responders, and remitters from non-remitters? Thank you.

Rob Barrow executive
#44

Yes, many thanks for that question, Chris. It's a genuinely exciting topic. As more information comes to light and as we release and publish additional findings from these analyses, we're quite eager to share some of what we've learned. Regarding the dynamics we're observing — naturally, we're always keen to identify baseline characteristics with predictive value for response; however, one particularly interesting discovery concerns response patterns along with treatment dynamics and what can be gleaned throughout the treatment period. So we keep gathering data from part B of the studies and keep clarifying further the response patterns and those patient pathways over the span of a full year. Once we can share things more specifically, I believe there are some genuinely compelling and possibly rather valuable insights we'll be in a position to provide. So it's a bit soon for me to give a complete answer, but once again, excellent question, and something we're very eager to put out into the world here before too long.

Chris Chen analyst
#45

All right. Appreciate it.

Patrick Trucchio analyst
#46

Thank you. Afternoon, everyone, and well done on the progress so far. The advantages in MDD and GAD, and possibly PTSD, are obviously quite evident. I'm curious whether you could speak to where DT120 might extend past that point over the longer term, while of course recognizing that we already have a sizable patient population across the current indications. Given the data you've seen, I'd like to know where you believe there could be longer-term potential.

Rob Barrow executive
#47

Yeah, good question. Thanks, Patrick. It's definitely too early for us to get into specifics about which indications we will or would be going after down the road. Yet our thinking is quite broad—not just about possibly widening the patient groups, but also about establishing reliable access points for care, so that no matter how someone presents or what their symptoms are like, we can reach into those additional populations, particularly ones that differ to some degree, whether by diagnosis or by symptoms, from the patients we treat now. And of course, we're also looking ahead to where we might extend the population further and to being precise about which patients within GAD, MDD, and PTSD could benefit, and in what ways. So this is something we're pursuing energetically and considering for the future. Once those plans are firmed up and we have a clear route toward possible expansion plus additional indications, we will definitely be keen to provide further details on that front as well.

Analyst analyst
#48

Hello, Poorna here, speaking in place of Ami. Thanks for letting us ask. Right now, how large is the number of GAD patients who receive treatment in clinics compared with TRD or MDD? And what do you think it will take to raise awareness among patients and physicians and to bring more patients into these clinics? Also, do you think uptake for MDD could be quicker than for GAD? Thank you.

Rob Barrow executive
#49

Yes, thanks very much for asking. As we look at these indications, we truly do not view them as completely separate from each other, and doing so would be somewhat strange given how much they overlap. Prescribing in some of the more recent years has likewise been shaped by the fact that new treatment options have, for almost the last 20 years, been nearly exclusively for MDD and not for GAD. There is considerable interplay between the absence of available treatments and the patterns of prescribing and treatment; but as we consider the opportunity, we consider it quite holistically, taking in both those GAD and MDD patients together. Matt, I don't know whether you'd like to add any further specifics regarding how we think about it.

Matt Wiley executive
#50

No, the sole additional thing I’d mention concerns referrals and referral networks for the clinics. A few are already established at this point, but we have a responsibility to make the case within psychiatrists’ offices so they know about DT120, should it be approved, and that we have a GAD indication, and so they can spot in their own practice those patients who might be suitable and whom they may wish to send to one of these clinics. GAD patients are already being treated in the clinics today. We know that from data. By our calculations, more than half of these SPRAVATO patients also have comorbid GAD, so they are receiving treatment. A great deal of solid work is underway to chart those referral networks and to make sure they have the right information at launch if we’re approved.

Analyst analyst
#51

All right. Appreciate it.

Rudy Li analyst
#52

Hi there, thanks for fielding my question. Could you give us more detail on the end-of-session checklist for DT120? Perhaps you could address the edge cases involving patients who require monitoring beyond eight hours. Typically, which step tends to be the main bottleneck or which items are, and how should those situations be managed in actual practice? Thank you.

Rob Barrow executive
#53

Yes, thank you very much, Rudy. We're quite confident on all fronts — regarding the data emerging from the studies, regarding how we're engaging with clinicians, and regarding how workable the DT120 profile is in those environments. Although there are definitely a few quite rare instances in which patients take somewhat more time to clear, we're in fact seeing some promising trends in that longitudinal data that we haven't yet been in a position to fully share. Also, once again, across all our interactions with sites delivering care at present, we have not observed any genuine cause for concern. There are a few anecdotes from certain studies involving, say, some of the extreme cases — and one specifically, where a patient drifted off to sleep and the site chose to let them sleep for a couple of hours rather than rousing them. Because of that, we were required to report it as monitoring that went beyond eight hours. Naturally, in real-world practice, if a person is sleeping and the site prefers to keep them there and allow them to sleep it off, that's completely acceptable. Making that call is at their discretion, but nothing we've seen thus far in the data strikes us as worrisome or as anything other than truly workable and well suited to a real-world setting.

Rudy Li analyst
#54

Thanks for the color. Very helpful.

Rob Barrow executive
#55

Thanks, Rudy.

Rob Barrow executive
#56

Thanks, everyone, for being with us once more today. This has been a truly thrilling year and a truly thrilling quarter. As we move toward the close of the year and prepare to launch into 2027, our excitement has never been greater about what our organization can achieve, or about DT120, or about the chance to make a genuinely profound difference in psychiatry. Thanks again for your presence here and for all the backing you've given us throughout, and we can't wait to be together again before long.

Operator operator
#57

Ladies and gentlemen, we appreciate your joining today's conference. That brings the program to a close. You're welcome to disconnect at this point. Everyone, have a wonderful day.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Definium Therapeutics, Inc. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to Definium Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.